Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease

Clin Neuropharmacol. Sep-Oct 1999;22(5):301-5.


We evaluated the efficacy of the nonergot dopamine receptor agonist pramipexole in 16 patients with advanced Parkinson's disease and marked rest tremor during an "on" period. The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor. Eleven patients received pramipexole. The first effects were seen with a pramipexole dose of 0.75 mg/d with a reduction of the tremor item A of Unified Parkinson's Disease Rating Scale (UPDRS III, "on" state) by 25% and of rigidity and akinesia by 22%. Under the highest dose, 4.5 mg/d, the tremor score was improved by 61% over baseline (p < 0.0056, Wilcoxon signed rank) and the sum of rigidity and akinesia items by 66% (p < 0.0038, Wilcoxon signed rank). Five patients received placebo and did not improve. Based on this sample of patients, the nonergot dopamine receptor agonist pramipexole appears to have a potent anti-rest tremor action while being effective against akinesia and rigidity.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Benzothiazoles
  • Dopamine Agonists / therapeutic use*
  • Humans
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Pramipexole
  • Severity of Illness Index
  • Thiazoles / therapeutic use*
  • Treatment Outcome
  • Tremor / drug therapy*


  • Antiparkinson Agents
  • Benzothiazoles
  • Dopamine Agonists
  • Thiazoles
  • Pramipexole